Last reviewed · How we verify
active: AFFITOPE AD02
At a glance
| Generic name | active: AFFITOPE AD02 |
|---|---|
| Also known as | AFFITOPE AD02 |
| Sponsor | Affiris AG |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006 (PHASE2)
- Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease (PHASE2)
- Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- active: AFFITOPE AD02 CI brief — competitive landscape report
- active: AFFITOPE AD02 updates RSS · CI watch RSS
- Affiris AG portfolio CI